featured
2021 Top Story in Cardiology: EMPEROR-Preserved—Empagliflozin in HFpEF
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461.
- Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. Commentary by: Braunwald E. PracticeUpdate. https://www.practiceupdate.com/content/empagliflozin-in-patients-with-hfpef/122909/62. September 2, 2021. Accessed December 5, 2021.
- FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction [press release]. Ridgefield, CT, and Indianapolis, IN: Eli Lilly and Company; September 9, 2021. https://investor.lilly.com/node/45556/pdf. Accessed December 5, 2021.
Disclosure statements are available on the authors' profiles: